[go: up one dir, main page]

MX2009005941A - Ensayos de diagnostico complementario para terapia de cancer. - Google Patents

Ensayos de diagnostico complementario para terapia de cancer.

Info

Publication number
MX2009005941A
MX2009005941A MX2009005941A MX2009005941A MX2009005941A MX 2009005941 A MX2009005941 A MX 2009005941A MX 2009005941 A MX2009005941 A MX 2009005941A MX 2009005941 A MX2009005941 A MX 2009005941A MX 2009005941 A MX2009005941 A MX 2009005941A
Authority
MX
Mexico
Prior art keywords
cancer therapy
diagnostic assays
bcl
family inhibitor
companion diagnostic
Prior art date
Application number
MX2009005941A
Other languages
English (en)
Inventor
Mark Gerald Anderson
Paul E Kroeger
Saul Howard Rosenberg
Stephen Kenneth Tahir
Christin Tse
John A Wass
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009005941A publication Critical patent/MX2009005941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para identificar pacientes con cáncer elegibles para recibir la terapia del inhibidor de la familia Bcl-2 y para supervisar la respuesta del paciente a la terapia del inhibidor de la familia Bcl-2, que comprende la evaluación de los niveles de expresión del conjunto de combinaciones del marcador biológico en las tablas 1, 2, 3, 4, 5, ó 6 en una muestra de tejido del paciente. Los métodos de la invención permiten más eficiencia en la identificación de pacientes para recibir la terapia del inhibidor de la familia Bcl-2 y de la determinación de la respuesta del paciente a la terapia.
MX2009005941A 2006-12-04 2007-12-04 Ensayos de diagnostico complementario para terapia de cancer. MX2009005941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87266806P 2006-12-04 2006-12-04
PCT/US2007/086382 WO2008070663A2 (en) 2006-12-04 2007-12-04 Companion diagnostic assays for cancer therapy

Publications (1)

Publication Number Publication Date
MX2009005941A true MX2009005941A (es) 2009-07-24

Family

ID=39493038

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005941A MX2009005941A (es) 2006-12-04 2007-12-04 Ensayos de diagnostico complementario para terapia de cancer.

Country Status (12)

Country Link
US (1) US20080199873A1 (es)
EP (1) EP2106451A4 (es)
JP (1) JP2010511407A (es)
KR (1) KR20090087491A (es)
CN (1) CN101611154A (es)
AU (1) AU2007329458A1 (es)
BR (1) BRPI0719563A2 (es)
CA (1) CA2671399A1 (es)
IL (1) IL198976A0 (es)
MX (1) MX2009005941A (es)
RU (1) RU2009125575A (es)
WO (1) WO2008070663A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011097476A1 (en) * 2010-02-04 2011-08-11 Indiana University Research And Technology Corporation 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen
CN103501795A (zh) * 2011-03-29 2014-01-08 新化学人股份有限公司 含有二氧化碳作为有效成分的抗肿瘤剂
US10871491B2 (en) * 2014-08-25 2020-12-22 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN105713963A (zh) * 2014-12-05 2016-06-29 上海药明康德新药开发有限公司 从福尔马林固定石蜡包埋的组织样品中检测基因表达的方法
SG11201900135YA (en) 2016-08-05 2019-02-27 Univ Michigan Regents N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
USRE50643E1 (en) 2018-01-10 2025-10-21 Recurium Ip Holdings, Llc Benzamide compounds
WO2019147014A1 (ko) * 2018-01-23 2019-08-01 기초과학연구원 연장된 단일 가이드 rna 및 그 용도
AU2019315466B2 (en) 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3094449C (en) 2018-07-31 2023-02-28 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN112213492B (zh) * 2019-07-09 2024-04-30 复旦大学 Clic4在制备放射治疗鼻咽癌制剂中的应用
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5953727A (en) * 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
ATE373725T1 (de) * 2001-10-30 2007-10-15 Ortho Clinical Diagnostics Inc Methoden zur feststellung von akute myeloischen leukämie
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
WO2006109086A2 (en) * 2005-04-15 2006-10-19 Astrazeneca Ab Method to predict the sensitivity of tumors to eg5 inhibitors
WO2007022588A1 (en) * 2005-08-24 2007-03-01 The Walter And Eliza Hall Institute Of Medical Research Method for assessing a response to an antiproliferative agent
JP2007159416A (ja) * 2005-12-09 2007-06-28 Bristol Myers Squibb Co ダサチニブの耐性の判別とその克服方法

Also Published As

Publication number Publication date
CN101611154A (zh) 2009-12-23
US20080199873A1 (en) 2008-08-21
WO2008070663A3 (en) 2009-04-02
RU2009125575A (ru) 2011-01-20
KR20090087491A (ko) 2009-08-17
IL198976A0 (en) 2010-02-17
AU2007329458A1 (en) 2008-06-12
BRPI0719563A2 (pt) 2013-12-10
EP2106451A4 (en) 2010-12-15
JP2010511407A (ja) 2010-04-15
CA2671399A1 (en) 2008-06-12
EP2106451A2 (en) 2009-10-07
WO2008070663A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
ATE511653T1 (de) Annexin zur beurteilung des krebsrisikos
MY195860A (en) Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
EP2406401A4 (en) METHOD FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF LUNG DISEASES AND KITS THEREOF FOR HEALTH-SPECIFIC ILLNESSIFICATION, ASSESSMENT, PREVENTION AND TREATMENT
WO2008082673A8 (en) Companion diagnostic assays for cancer therapy
SG179070A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico
WO2009122444A3 (en) Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro

Legal Events

Date Code Title Description
FA Abandonment or withdrawal